ArticleFrontiers in oncology2026
Prevalence and clinicopathological correlates of MSI/dMMR in colorectal cancer: a prospective multicenter registry study from Russia.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05495776 (Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microsatellite instability/mismatch repair deficiency are well-established predictive biomarkers for immune checkpoint inhibitor therapy and are used to identify candidates for Lynch syndrome screening in colorectal cancer. In Russia, population-level data on their prevalence are limited - most published series are small, retrospective, or enriched for metastatic disease. Methods: We performed a pre-specified cross-sectional analysis within a prospective non-interventional registry that enrolled consecutive, unselected patients with primary colorectal adenocarcinoma at six specialised centres in Moscow between August 2022 and December 2025. Of 2,140 patients registered, 2,101 were included after exclusion of synchronous multiple primary tumours. Mismatch repair status was determined by immunohistochemistry, polymerase chain reaction-based microsatellite analysis, or both, following each centre's standard diagnostic protocol. Logistic regression was used to identify independent clinicopathological predictors of mismatch repair deficiency. Results: Mismatch repair deficiency was detected in 220 patients, giving an overall prevalence of 10.5% (95% confidence interval 9.2-11.8%). Prevalence was 23.2% in right-sided tumours, 6.2% in left-sided tumours, and 2.8% in rectal tumours (p<0.001). Among graded tumours, poorly differentiated cases had a rate of 32.4% versus 8.4% in low-grade tumours (p<0.001). Female patients accounted for 70.0% of mismatch repair-deficient cases versus 50.1% of proficient cases (p<0.001). On multivariate analysis, right-sided location (odds ratio 3.67; 95% confidence interval 2.57-5.31), high-grade histology (odds ratio 4.15; 95% confidence interval 2.79-6.13), and female sex (odds ratio for male sex 0.49; 95% confidence interval 0.34-0.69) were independently associated with mismatch repair deficiency, while advanced stage (odds ratio 0.64; 95% confidence interval 0.46-0.89) and older age (odds ratio 0.98 per year; 95% confidence interval 0.97-1.00) showed inverse associations. Despite these associations, a meaningful proportion of mismatch repair-deficient cases occurred outside conventional high-risk clinicopathological groups. Conclusion: Mismatch repair deficiency prevalence in unselected Russian colorectal cancer patients matches international estimates. Clinicopathological features alone are not sufficient to identify all affected patients. To our knowledge, this is the largest prospective multicentre series from Russia to date. Our data support universal mismatch repair testing rather than selective testing based on clinical or pathological criteria (ClinicalTrials.gov, NCT05495776).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.